Sporadic multiple intracranial meningioma does not infer worse patient outcomes: results from a case control study


Islim, Abdurrahman I, Lee, Jing X, Mustafa, Mohammad A, Millward, Christopher P ORCID: 0000-0001-7727-1157, Gillespie, Conor S, Richardson, George E, Taweel, Basel A ORCID: 0000-0002-6157-2438, Chavredakis, Emmanuel, Mills, Samantha J, Brodbelt, Andrew R et al (show 1 more authors) (2023) Sporadic multiple intracranial meningioma does not infer worse patient outcomes: results from a case control study. JOURNAL OF NEURO-ONCOLOGY, 161 (2). pp. 287-295.

[img] Text
2022_Mutliple meningioma_paper.docx - Author Accepted Manuscript
Download (414kB)

Abstract

<h4>Background</h4>Sporadic multiple meningioma are uncommon. Population-based data suggests that these patients have a reduced overall survival when compared to patients with solitary meningioma. The aim of this study was to investigate the clinical outcomes in multiple and solitary meningioma.<h4>Methods</h4>A single-center matched cohort study (2008-2018) was performed. Patients with synchronous multiple meningioma at presentation, with no history of prior intracranial radiation, concurrent hormone replacement therapy or features of NF2-schwannomatosis were included. Eligible patients were matched 1:1 to patients with solitary meningioma. Outcomes of interest were occurrence of an intervention, recurrence, new meningioma development and mortality.<h4>Results</h4>Thirty-four patients harboring 76 meningioma at presentation were included. Mean age was 59.3 years (SD = 13.5). Thirty-one (91.2%) were female. The median number of meningioma per patient was 2 (range 2-6). Eighteen patients (52.9%) were symptomatic at presentation. Median overall follow-up was 80.6 months (IQR 44.1-99.6). Compared to patients with a sporadic meningioma, there was no difference in intervention rates (67.6% vs 70.6%, P = 0.792). Eight patients (34.8%) with a multiple meningioma had a WHO grade 2 meningioma compared to 7 (29.2%) with a solitary meningioma (P = 0.679). Median recurrence-free survival was 89 months (95% CI 76-104) with no difference between the two groups (P = 0.209). Mean overall survival was 132 months (95% CI 127-138) with no difference between the two groups (P = 0.860). One patient with multiple meningioma developed two further new meningioma 36 months following diagnosis.<h4>Conclusion</h4>Sporadic multiple meningioma may not have worse clinical outcomes. Management of patients with sporadic multiple meningioma should be tailored towards the symptomatic meningioma or high-risk asymptomatic meningioma.

Item Type: Article
Uncontrolled Keywords: Humans, Meningioma, Meningeal Neoplasms, Case-Control Studies, Retrospective Studies, Cohort Studies, Follow-Up Studies, Middle Aged, Female, Male
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 13 Jun 2023 15:08
Last Modified: 15 Nov 2023 02:30
DOI: 10.1007/s11060-022-04184-4
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3170959
Dimensions
Altmetric
CORE (COnnecting REpositories)